JaredDavidAcobaMD

Oncology • Honolulu, HI

Physician

Join to view full profile

Dr. Acoba is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Acoba's full profile

Already have an account?

Office
321 N Kuakini St
Suite 412
Honolulu, HI 96817
Phone+1 808-531-8521

Fax+1 808-772-4036

Education & Training

Oregon Health & Science University (OHSU Health)Fellowship, Hematology and Medical Oncology, 2004 - 2007
University of HawaiiResidency, Internal Medicine, 2001 - 2004
University of Hawaii, John A. Burns School of MedicineClass of 2001

Certifications & Licensure

OR State Medical License 2007 - Present
HI State Medical License 2001 - 2026
WA State Medical License 2005 - 2007
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012-2013

Clinical Trials

Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer Start of enrollment: 2011 Apr 01
Terminated
Phase 3
Gemcitabine and Oxaliplatin in the Management of Metastatic Pancreatic Cancers With Low Expression of ERCC1 Start of enrollment: 2012 Jan 01
Withdrawn
Phase 2
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer Start of enrollment: 2014 Oct 03
Active, not recruiting
Phase 3
A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY) Start of enrollment: 2015 May 06
Active, not recruiting
Phase 3
A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma Start of enrollment: 2015 Sep 14
Active, not recruiting
Phase 3
TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver Cancer Start of enrollment: 2019 Dec 19
Recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

1212 citations
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.
Nicole M. Kuderer, Toni K. Choueiri, Dimpy P. Shah, Yu Shyr, Samuel M. Rubinstein
Lancet. 2020-06-20
35 citations
Creating a “culture of research” in a community hospital: Strategies and tools from the National Cancer Institute Community Cancer Centers Program
Eileen Dimond, Diane St. Germain, Lianne Nacpil, Howard A. Zaren, Sandra M Swanson
Clinical Trials. 2015-02-17
222 citations
Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium.
Petros Grivas, Ali Raza Khaki, Trisha Wise-Draper, Benjamin French, C. Hennessy
Annals of Oncology. 2021-06-01

Press Mentions

UH Cancer Center, Hawaii Cancer Consortium Join National COVID-19 StudyApril 21st, 2020

Professional Memberships

American Society of Clinical Oncology - ASCO
Member